Effects of ICD implantation on quality-adjusted life years in patients with congestive heart failure

International Journal of Cardiology

Volumn 123, Issue 2, 2008, Pages 213-216

  Ozasa, Neiko ^a   Morimoto, Takeshi ^a   Furukawa, Yutaka ^a   Shizuta, Satoshi ^a   Nishiyama, Kei ^a   Kita, Toru ^a   Kimura, Takeshi ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Decision analysis; Implantable cardioverter defibrillator; Primary prevention; Quality adjusted life years; Reduced left ventricular ejection fraction

Indexed keywords

ARTICLE; CONGESTIVE HEART FAILURE; DECISION MAKING; DEFIBRILLATOR; HEART DEATH; HEART EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SUDDEN DEATH; TREATMENT OUTCOME;

DECISION SUPPORT TECHNIQUES; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HUMANS; QUALITY OF LIFE;

EID: 37049008469     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.11.216     Document Type: Article

References (12)

1. Jessup M., and Brozena S. Heart failure. N Engl J Med 348 20 (2003) 2007-2018
2. Gregoratos G., Abrams J., Epstein A.E., et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 106 16 (2002) 2145-2161
3. Alter P., Waldhans S., Plachta E., Moosdorf R., and Grimm W. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol 28 9 (2005) 926-932
4. Namerow P.B., Firth B.R., Heywood G.M., Windle J.R., and Parides M.K. Quality-of-life six months after CABG surgery in patients randomized to ICD versus no ICD therapy: findings from the CABG Patch Trial. Pacing Clin Electrophysiol 22 9 (1999) 1305-1313
5. Sanders G.D., Hlatky M.A., and Owens D.K. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 353 14 (2005) 1471-1480
6. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 3 (2005) 225-237
7. DiMarco J.P. Implantable cardioverter-defibrillators. N Engl J Med 349 19 (2003) 1836-1847
8. Morimoto T., and Fukui T. Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J Epidemiol 12 2 (2002) 160-178
9. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 9386 (2003) 767-771
10. Morimoto T., Fukui T., Koyama H., Noguchi Y., and Shimbo T. Optimal strategy for the first episode of primary spontaneous pneumothorax in young men. A decision analysis. J Gen Intern Med 17 3 (2002) 193-202
11. Lewis E.F., Johnson P.A., Johnson W., Collins C., Griffin L., and Stevenson L.W. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 20 9 (2001) 1016-1024
12. Havranek E.P., McGovern K.M., Weinberger J., Brocato A., Lowes B.D., and Abraham W.T. Patient preferences for heart failure treatment: utilities are valid measures of health-related quality of life in heart failure. J Card Fail 5 2 (1999) 85-91